Ann: Phosphagenics and Quigley Corp form JV for O, page-11

re: Ann: Phosphagenics and Quigley Corp form ... Potential back door listing for POH into a Nasdaq company for its Peronal care and Pharma business.

The USA is a massive market for OTC and this is a major opportunity for POH to partner and underpin an OTC product family rollout as early as 2011.

This is also a very fast growing market. OTC sales for example for GlaxoSmithKline (GSK) grew over 35% b/n 2007 and 2009.

I have just hit the phones to discuss this ann with some learned colleagues. This new venture according to some of my insider friends from Pharma could be a USD$200 Mill company in next to no time. As a 50% stakeholder in this new venture- we take existing non prescription drugs - bolting on our TPM to provide a unique and clinically proven product range with many advantages over competitor non prescription drugs.

Again take Nicotein Patches as an example of a market opportunity for this new POH venture. Patient compliance in using Nicobate patches is low since the active causes massive irritation to the site of application. In a ten Week Step-Down program- thats a lot of irritation to put up with. A TPM Nicotine Patch will deliver the active with increased efficacy and no irritaion or tolerance issues at a price point comparable to existing therapies.

Our new broker will now have to rewrite their BUY report.

KC